Facing the increasingly strict environment for the regulatory approval of new drugs, intellectual property issues are essential to the success of research and development of new therapies by biopharmaceutical companies. Since its inception, JOINN Bio has developed an engineered cell line with full intellectual property rights. This helps to reduce the large amount of intellectual property expenses in the late commercialization of novel therapies. Currently, JOINN Bio has established a host cell system that satisfies the requirement from pilot to commercial production. In addition, JOINN Bio has established quality standard, release assays, and in-depth structural characterization for monoclonal antibodies and recombinant protein drugs.